GlassScriptPhysician profile
Iris Wingrove
NPI 1710008792
$16,651.39
in general payments reported to CMS, 2019-2025
59 companies · $3,425 in 2025
The $3,425 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $1,891 · 2021: $2,202 · 2022: $2,036 · 2023: $2,324 · 2024: $3,327 · 2025: $3,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,801 · Consulting Fee: $150 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,801.42 |
| Consulting Fee | $150.00 |
| Education | $124.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,725.85 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Teva Pharmaceuticals USA, INC. | $1,471.26 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Pfizer INC. | $1,128.68 | 2023-2025 | |
| Lilly USA, LLC | $948.49 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Sk Life Science, INC. | $899.70 | 2020-2025 | Xcopri |
| Arbor Pharmaceuticals, INC. | $868.33 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $828.82 | 2019-2025 | Nuplazid |
| Amgen INC. | $794.65 | 2019-2024 | Aimovig |
| Ucb, INC. | $741.25 | 2019-2025 | Briviact, Nayzilam |
| Lundbeck LLC | $586.25 | 2020-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $444.48 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $421.37 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $392.62 | 2022 | |
| Upsher-Smith Laboratories LLC | $389.79 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $385.86 | 2019-2025 | Rylaze |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $318.75 | 2023-2025 | Nuedexta, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $278.67 | 2023-2025 | Hyqvia, Gammagard |
| Biogen, INC. | $272.88 | 2021-2025 | Leqembi |
| Kyowa Kirin, INC. | $263.27 | 2019-2023 | Nourianz |
| Octapharma USA, INC. | $249.19 | 2023-2025 | Panzyga |
| Mdd US Operations, LLC | $240.00 | 2022-2025 | Gocovri, Gocovri, Apokyn |
| Supernus Pharmaceuticals, INC. | $236.50 | 2019-2024 | Qelbree |
| Amneal Pharmaceuticals LLC | $219.44 | 2024-2025 | Crexont |
| Allergan, INC. | $207.35 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $203.65 | 2019-2023 | Ultomiris |
| Argenx US, INC. | $164.87 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Idorsia Pharmaceuticals US INC | $163.61 | 2023-2025 | Quviviq, Quviviq |
| Csl Behring | $162.22 | 2019-2025 | Hizentra |
| Almatica Pharma LLC | $154.59 | 2021 | |
| Scilex Pharmaceuticals INC. | $123.70 | 2023-2024 | Ztlido |
| Grifols USA, LLC | $122.07 | 2019-2022 | |
| Zyla Life Sciences, INC. | $116.37 | 2020 | |
| Avanir Pharmaceuticals, INC. | $113.75 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $99.93 | 2019-2021 | |
| Abbott Laboratories | $95.95 | 2023-2024 | Proclaim, Prodigy |
| Neos Therapeutics, LP | $94.14 | 2024-2025 | Adzenys Xr-Odt |
| Neurelis, INC. | $88.46 | 2020-2024 | Valtoco |
| Sunovion Pharmaceuticals INC. | $54.03 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $50.71 | 2020-2025 | Acthar |
| Hospira, INC. | $48.04 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $45.37 | 2022-2025 | Jornay Pm |
| Otter Pharmaceuticals, LLC | $42.55 | 2024 | Sympazan |
| Impel Pharmaceuticals LLC | $39.74 | 2024-2025 | Trudhesa |
| Romark Laboratories, Lc | $37.78 | 2019 | |
| Azurity Pharmaceuticals, INC. | $35.54 | 2025 | Horizant |
| Tonix Medicines, INC. | $33.37 | 2025 | Zembrace Symtouch |
| Emd Serono, INC. | $29.08 | 2023 | |
| Kedrion Biopharma, INC. | $24.98 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Sumitomo Pharma America, INC. | $24.69 | 2023-2024 | Aptiom |
| Eisai INC. | $22.05 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $20.57 | 2025 | Lumryz |
| Assertio Therapeutics, INC. | $17.91 | 2020 | |
| Currax Pharmaceuticals LLC | $17.49 | 2022 | |
| Boston Scientific Corporation | $17.26 | 2022 | |
| Akcea Therapeutics, INC. | $16.12 | 2021 | |
| Promius Pharma LLC | $16.11 | 2019 | |
| Merck Sharp & Dohme LLC | $15.57 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.54 | 2019 | |
| Redhill Biopharma INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Wingrove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.